Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 56,491 | 913 | 3,087 | 2,353 | 9,165 |
| Marketable Securities | 41,053 | 2,330 | 4,854 | 7,396 | 4,087 |
| Other current assets | 81 | 666 | 306 | 207 | 220 |
| TOTAL | $98,451 | $4,190 | $8,603 | $10,808 | $14,211 |
| Non-Current Assets | |||||
| PPE Net | 47 | 54 | 60 | 67 | 73 |
| Other Non-Current Assets | 101 | 133 | 164 | 194 | 222 |
| TOTAL | $149 | $187 | $224 | $260 | $296 |
| Total Assets | $98,600 | $4,377 | $8,827 | $11,068 | $14,507 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 943 | 2,601 | 1,518 | 1,574 | 1,029 |
| Accrued Expenses | 2,680 | 2,161 | 2,035 | 2,508 | 2,260 |
| TOTAL | $3,734 | $4,908 | $3,705 | $4,233 | $3,439 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 26 | 58 | 90 |
| TOTAL | $N/A | $N/A | $26 | $58 | $90 |
| Total Liabilities | $3,734 | $4,908 | $3,730 | $4,291 | $3,529 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 74,342 | 67,193 | 7,464 | 6,477 | 6,477 |
| Common Shares | 69 | 8 | 7 | 7 | 6 |
| Retained earnings | -94,421 | -82,288 | -76,510 | -71,550 | -66,901 |
| Other shareholders' equity | -37 | 2 | -1 | -2 | 1 |
| TOTAL | $94,866 | $-531 | $5,097 | $6,777 | $10,978 |
| Total Liabilities And Equity | $98,600 | $4,377 | $8,827 | $11,068 | $14,507 |